Count on the Advancement of DNA Medicine with Inovio Stock



a close up of a piece of paper: the inovio (INO) logo covered up by pills and a syringe


© Source: Ascannio / Shutterstock.com
the inovio (INO) logo covered up by pills and a syringe

Too often, traders tend to pigeonhole certain stocks. For example, some folks might think of Inovio Pharmaceuticals (NASDAQ:INO) as a Covid-19 vaccine company and INO stock as nothing more than a novel coronavirus stock.



a close up of a piece of paper: the inovio (INO) logo covered up by pills and a syringe


© Provided by InvestorPlace
the inovio (INO) logo covered up by pills and a syringe

Don’t get me wrong. Inovio absolutely is part of the nationwide and global battle against the coronavirus. But there’s no need to pigeonhole INO as just a coronavirus stock.

The company works diligently to develop DNA medicines to treat a range of infectious diseases and cancers. There’s positive news about Inovio’s development of its Covid-19 vaccine candidate, INO-4800, but there’s also good news in other departments.

Therefore, it’s worth investigating both Inovio’s Covid-19 vaccine efforts as well as the company’s progress in other areas. That way, you can get a complete picture of this fascinating biotech company with breakout potential.

INO Stock at a Glance

If the market is telling us anything about INO stock, it’s that the shares are underappreciated and undervalued. You might even say that INO is one of the biotech sector’s most compelling bargains at the moment.

INO stock achieved its 52-week high of $31.71 on June 29, but somehow the market decided that this wasn’t the right price for the stock. As a result, a gradual sell-off commenced.

Loading...

Load Error

At the close of Nov. 24, INO stock settled slightly above $10 per share. Sometimes people say that they like to buy low and sell high. When the time comes to buy a stake in a promising company at a low price, however, those same traders tend to chicken out.

If you hesitate, you might miss out on a rare opportunity with INO stock. Even if you’re only thinking relatively short-term (i.e., as a swing trader), there’s potential here. INO has a tendency to spike quickly from time to time, just like it did in mid-September. This could easily happen again if there’s good news.

Not Just Covid-19

I’m going to take a different approach from many commentators and veer away from the topic of Covid-19 vaccine candidates. Let’s not discount the significance of the other conditions that Inovio is working to address.

One example is INO-3107, Inovio’s DNA medicine candidate designed to treat Recurrent Respiratory Papillomatosis (RRP). Inovio just dosed its first subject with INO-3107 in a Phase 1/2 clinical trial for this condition.

RRP is a very unfortunate and rare ailment. Caused by certain types of human papillomavirus (HPV), RRP is incurable and causes non-cancerous tumor growths that lead to life-threatening airway obstructions.

Usually, surgery is used to treat RRP. Furthermore, sometimes patients need multiple surgeries, which can severely impact their quality of life. The U.S. Food and Drug Administration (FDA) already granted INO-3107 Orphan Drug Designation, so it’s great to hear that there’s progress in developing this less invasive treatment.

Advancing Other DNA Medicines

For

Read more

Goldfinch Bio Presents Clinical Data from Phase 1 Trial Supporting Advancement of GFB-887 as a Precision Medicine for Patients with Kidney Diseases

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced for the first time results from its Phase 1 clinical trial evaluating GFB-887, a first-in-class highly potent and selective inhibitor of Transient Receptor Potential Canonical Channel 5 (TRPC5), in healthy volunteers. The data are being presented today at the virtual American Society of Nephrology (ASN) Kidney Week 2020 Annual Meeting.

Goldfinch Bio is developing GFB-887 as a precision medicine for patients with kidney diseases characterized by overactivation of the TRPC5-Rac1 pathway, including focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN). Overactivation of the TRPC5-Rac1 pathway leads to injury of podocytes, which are cells lining the kidney that, in their healthy state, prevent essential protein loss (proteinuria). Injury to podocytes causes podocyte loss, proteinuria and, eventually, kidney failure. TRPC5-Rac1 pathway overactivation is the key cause of disease in a substantial portion of FSGS and DN patients, and there are currently no approved drugs that specifically target the TRPC5-Rac1 pathway in these diseases.

“We are excited to share these first-in-human data, which demonstrate that GFB-887 is well-tolerated and suggest a dose-dependent reduction in urinary Rac1, confirming GFB-887 target engagement in the podocyte,” said Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio. “Suppressing the TRPC5-Rac1 pathway has the potential to deliver clinically meaningful benefit to patients by reducing proteinuria and, as a result, preserving native kidney function. Supported by the Phase 1 data, we are now underway with our Phase 2 TRACTION-2 study of GFB-887 in FSGS and DN, as we continue to advance our mission of protecting patients from the inevitability of dialysis and kidney transplant by delivering precision medicines for subsets of kidney disease.”

Data from the Phase 1 Clinical Trial

The primary objective of the randomized, double-blinded, placebo-controlled trial was to assess the safety, tolerability, pharmacokinetic (PK) profile and pharmacodynamics (PD) of GFB-887 in healthy volunteers. A key exploratory objective was to characterize changes in urinary Rac1. Urinary Rac1 concentration may predict therapeutic response to TRPC5 inhibition.

The study enrolled 70 subjects, who were randomized four to one to receive GFB-887 at seven dose levels (ranging from 5 mg to 900 mg) or placebo.

Primary Objective: Safety, Tolerability and PK Data

GFB-887 was observed to be well-tolerated at all doses. There were no dose-limiting toxicities, severe adverse events (AEs) or abnormalities in laboratory or clinical assessments. In total, 38 percent of subjects who received GFB-887 reported AEs, compared to 21 percent of subjects treated with placebo. GFB-887-treated subjects reported headache more frequently than placebo-treated subjects (28.6% versus 7.2% respectively). The only other AE that was reported in two or more GFB-887-treated subjects was nausea (3.6%). Slight, asymptomatic reductions in blood pressure were observed in subjects treated at the highest doses.

The PK profile of GFB-887 is consistent with once-daily dosing, with a half-life ranging from 55 to 68 hours. A single 40 mg dose was also shown to exceed the preclinical

Read more

Advancement of ultrasound theranostic techniques in medicine and biology

Announcing a new article publication for BIO Integration journal. In this editorial, Co-Editor-in-Chief, Pingtong Huang considers an integrated approach to ultrasound imaging in medicine and biology.

Ultrasound imaging is an important method for clinical disease screening, early diagnosis, and non-invasive guidance.

The development and research pertaining to ultrasound contrast agents for ultrasound molecular imaging underlies the advancement of ultrasound targeted technologies and is the driving force for the progression of ultrasound molecular imaging.

The utilization of ultrasound-mediated microbubble cavitation to augment the movement of genes, drugs, and antibodies across the vascular endothelial barrier to realize intracellular delivery has created new opportunities for applications in biology and clinical transformation.

Sonodynamic therapy has emerged as a favorable option for the minimally-invasive treatment of solid cancers.

The compounded utilization of ultrasound and a sonosensitizer drug to produce cytotoxic reactive oxygen species in and around neoplastic cells forms the basis of sonodynamic therapy.

In the future, the rise in cross-disciplinary and interdisciplinary cooperation will continue to promote the advancement of ultrasound theranostic techniques with additional accomplishments in clinical trials and basic research which could have extensive benefits to human health.

BIO Integration is fully open access journal which will allow for the rapid dissemination of multidisciplinary views driving the progress of modern medicine.

As part of its mandate to help bring interesting work and knowledge from around the world to a wider audience, BIOI will actively support authors through open access publishing and through waiving author fees in its first years.

Also, publication support for authors whose first language is not English will be offered in areas such as manuscript development, English language editing and artwork assistance.

Source:

Journal reference:

Huang, P., An Integrated Approach to Ultrasound Imaging in Medicine and Biology. BIO Integration. doi.org/10.15212/bioi-2020-0036.

Source Article

Read more

Technological Advancement in Health Communication in Less Developed Countries

Direct communication in health care can take place via forms of social media such as Skype, zoom and video conferencing. Traditional forms of communication such as telephone, notes and letters can continue to be used for information sharing between health providers and patients. For example, doctors and patients can text and send messages to one another. It is imperative that social media messaging be used to reduce the time taken to obtain knowledge on patient condition and general wellbeing.

The use of social media communication tools should not make indirect communication obsolete. In instances of technology resistance and lack of access to social media, health providers will be required to communicate face to face with patients and their relatives. Sometimes it may be easier and faster to communicate with patients via other media such as third parties. Doctors and patients can communicate via third parties such as nurses, personal caregivers, family and relatives of patients who may be unable to communicate. In other instances, it may be advantageous for family or caregivers to inform patients of their condition. A spouse or parent may be empathetic in conveying negative news to patients.

As a small island developing nation, Trinidad and Tobago faces serious health challenges that can be minimized by appropriate investment in social media technology. The major challenges include shortage of ambulances, bed shortages, and acute shortage of highly specialized medical knowledge and practice. Three additional acute problems are hospital overcrowding, limited availability of biomedical technology and drug shortages. These problems are exacerbated by traffic congestion that results from poor road infrastructure. Health and infrastructural challenges often combine to impact the quality of healthcare for patients with limited access to health facilities negatively.

This paper proposes that the quality of patient care for less critically ill patients can be enhanced by the adoption of social media tools that will enable doctors and other health providers to see and hear their patients in remote sites such as specialized care facilities and patient residences. The main intention of social media usage is to reduce overcrowding, improve access to healthcare, promote effective pain management and reduce patient death or mortality. Many patients can be released from hospital and be cared for at convalescent and private homes where providers can monitor and evaluate their progress via Skype, video conferencing, zoom or other appropriate technology.

The state can promote technological advancement and innovation to make social media tools widely accessible, highly reliable and very efficient. Investment in innovation should lead to the introduction of local media technology that can enhance the phenomenon of multiple users at the same time. For instance, doctors, pharmacists, nurses and other health providers should be able to interface simultaneously in order to ensure patients receive the best care. The doctor will maintain the primary provider role but should be able to take advice from other providers who may spend more communication time with patients. Finally after health providers have attained a position of consensus on the way forward, patients and …

Read more